Equities Research Analysts’ Updated EPS Estimates for March, 20th (AAPL, AIG, ALNY, ALRM, ALSMY, ALXN, ARCO, ASPU, ATEN, AXTI)

Equities Research Analysts’ updated eps estimates for Monday, March 20th:

Apple (NASDAQ:AAPL) had its overweight rating reissued by analysts at Piper Jaffray Companies. Piper Jaffray Companies currently has a $155.00 target price on the stock.

American International Group (NYSE:AIG) had its buy rating reaffirmed by analysts at Royal Bank of Canada. The firm currently has a $71.00 target price on the stock.

Alnylam Pharmaceuticals (NASDAQ:ALNY) had its buy rating reiterated by analysts at FBR & Co.

AlarmCom Hldg (NASDAQ:ALRM) was upgraded by analysts at Zacks Investment Research from a hold rating to a buy rating. Zacks Investment Research currently has $35.00 target price on the stock. According to Zacks, “Alarm.com Holdings, Inc. offers interactive security solutions for home and business owners. The Company offers security systems which include image sensor, crash and smash protection, web control, mobile access and video monitoring. Alarm.com Holdings, Inc. is based in VIENNA, United States. “

ALSTOM (OTCMKTS:ALSMY) was downgraded by analysts at Zacks Investment Research from a hold rating to a sell rating. According to Zacks, “Alstom SA develops and markets systems, equipment and services for the railway sector. Its product includes bogies, traction systems, electrification, track laying and urban integrated solution. It also offers services such as parts and repairs, maintenance, customisation, modernisation and support services. Alstom SA is headquartered in France. “

Alexion Pharmaceuticals (NASDAQ:ALXN) had its outperform rating reiterated by analysts at Leerink Swann.

Arcos Dorados Holding (NYSE:ARCO) was downgraded by analysts at Zacks Investment Research from a hold rating to a sell rating. According to Zacks, “Arcos Dorados Holdings Inc. operates as a franchisee of McDonald’s with its operations divided in Brazil; North Latin America division; South Latin America and the Caribbean division. It also runs quick service restaurants in Latin America and the Caribbean. It has operations in territories in Latin America and the Caribbean, including Argentina, Aruba, Brazil, Chile, Colombia, Costa Rica, Curaçao, Ecuador, French Guiana, Guadeloupe, Martinique, Mexico, Panama, Peru, Puerto Rico, Uruguay, the U.S. Virgin Islands of St. Croix and St. Thomas, and Venezuela. Arcos Dorados Holdings Inc. is headquartered in Buenos Aires, Argentina. “

Aspen Group (OTCBB:ASPU) was upgraded by analysts at Zacks Investment Research from a sell rating to a hold rating. According to Zacks, “Aspen Group, Inc. is an online post-secondary education company. It offers certificate programs and associate, bachelor, master, and doctoral degree programs in a range of areas, including business and organization management, education, nursing, information technology, and general studies. Aspen Group, Inc. is headquartered in Denver, Colorado. “

A10 Networks (NYSE:ATEN) was upgraded by analysts at Zacks Investment Research from a sell rating to a hold rating. According to Zacks, “A10 Networks, Inc. provides software based application networking solutions. Its solutions enable enterprises, service providers, Web giants, and government organizations to enhance, secure, and optimize the performance of their data center applications and networks. The company delivers its solutions on optimized hardware appliances and as virtual appliances across its Thunder Series and AX Series product families. A10 Networks, Inc. is headquartered in San Jose, California. “

AXT (NASDAQ:AXTI) was downgraded by analysts at Zacks Investment Research from a buy rating to a hold rating. According to Zacks, “AXT, Inc., designs, develops, manufactures and distributes high-performance compound semiconductor substrates, as well as opto-electronic semiconductor devices such as high-brightness light emitting devices, and vertical cavity surface emitting lasers. “

Acuity Brands (NYSE:AYI) was downgraded by analysts at Zacks Investment Research from a hold rating to a sell rating. According to Zacks, “Acuity Brands, Inc. is comprised of the Acuity Lighting Group and Acuity Specialty Products. The Acuity Lighting Group is the world’s largest lighting fixture manufacturer and includes brands such as Lithonia Lighting, Holophane, Peerless, and Hydrel. Acuity Specialty Products is a leading provider of specialty chemicals and includes brands such as Zep, Enforcer, and Selig. “

AstraZeneca plc (NYSE:AZN) had its outperform rating reissued by analysts at Leerink Swann.

Banco Bilbao Vizcaya Argentaria SA (NASDAQ:BBVA) was upgraded by analysts at Zacks Investment Research from a sell rating to a hold rating. According to Zacks, “Banco Bilbao Vizcaya is engaged in a wide variety of banking, financial and related activities in Spain. “

BioCryst Pharmaceuticals (NASDAQ:BCRX) was downgraded by analysts at Zacks Investment Research from a buy rating to a hold rating. According to Zacks, “BioCryst Pharmaceuticals, Inc. is a leader in the use of crystallography and structure-based drug design for the development of novel therapeutics to treat cancer, cardiovascular diseases, autoimmune diseases, and viral infections. The company is advancing multiple internal programs toward potential commercialization including Fodosine in oncology, BCX-4208 in transplantation and autoimmune diseases and peramivir in seasonal and life threatening influenza. BioCryst has a worldwide partnership with Roche for the development and commercialization BCX-4208, and is collaborating with Mundipharma for the development and commercialization of Fodosine in markets across Europe, Asia, Australia and certain neighboring countries. “

Belden (NYSE:BDC) was upgraded by analysts at Zacks Investment Research from a sell rating to a hold rating. According to Zacks, “Belden Inc is engaged in the design, manufacture and retail of cable, connectivity, and networking products in markets including industrial automation, enterprise, transportation, infrastructure, and consumer electronics. The Company’s products find its application in the industrial automation, enterprise, education, healthcare, entertainment and broadcast, sound and security, transportation, infrastructure, consumer electronics and other industries. Belden has manufacturing capabilities in North America, Europe, and Asia, and a market presence in nearly every region of the world. Belden Inc is based in St. Louis, Missouri. “

BioDelivery Sciences International (NASDAQ:BDSI) had its buy rating reiterated by analysts at FBR & Co. The firm currently has a $4.00 target price on the stock. The analysts wrote, “BioDelivery reported 4Q16 results after the close on March 16. On the morning of March 17, management hosted a call to provide an update on 2017 progress. The company recently announced that it has entered into a senior credit facility with affiliates of CRG LP , which is a healthcare-focused investment firm, and currently has debt financing of up to $75M secured, with initial proceeds extending the company’s cash runway into 2H18.””

Berkshire Hills Bancorp (NASDAQ:BHLB) was downgraded by analysts at Zacks Investment Research from a hold rating to a sell rating. According to Zacks, “Berkshire Hills Bancorp, Inc. is a bank holding company. Through its subsidiaries, the company is engaged as a community bank that accepts retail deposits from the general public in the areas surrounding its full-service banking offices and uses those funds,together with funds generated from operations and borrowings, to originate residential mortgage loans, commercial business and real estate loans and consumer loans, primarily indirect automobile loans. “

Sothebys (NYSE:BID) was downgraded by analysts at Zacks Investment Research from a hold rating to a sell rating. According to Zacks, “Sotheby’s Holdings, Inc. is one of the world’s second largest auctioneers of fine arts, antiques and collectibles, offering property in collecting categories, among them paintings, jewelry, decorative arts, and books. Sotheby’s Holdings, Inc is the parent company of Sotheby’s worldwide auction businesses, art-related financing and private sales activities. The Company operates in countries, with principal salesrooms located in New York and London. The company also regularly conducts auctions in other salesrooms around the world, including Australia, Hong Kong, France, Italy, the Netherlands, Switzerland and Singapore. “

Celgene (NASDAQ:CELG) had its market perform rating reissued by analysts at Leerink Swann.

Energy Focus (NASDAQ:EFOI) had its hold rating reissued by analysts at FBR & Co.

Endo International plc – (NASDAQ:ENDP) had its market perform rating reissued by analysts at Leerink Swann.

Energy Recovery (NASDAQ:ERII) had its buy rating reaffirmed by analysts at FBR & Co. They currently have a $16.00 price target on the stock. The analysts wrote, “Heading into the NDR that FBR will host this week with President and CEO Joel Gay, CFO Chris Gannon, and Managing Director, IR and Corporate Development Brian Uhlmer, we are updating our model for 4Q16 results (our annual EPS/EBITDA are unchanged) and highlighting several topics for ERII’s oil & gas division that our meetings should delve into and further explicate. We believe 2017 will reaffirm ERII’s extraordinary oil & gas growth potential and that the stock is offering compelling risk/reward at its current level.””

Eco-Stim Energy Solutions (NASDAQ:ESES) had its buy rating reiterated by analysts at FBR & Co. They currently have a $1.85 price target on the stock. The analysts wrote, “We are updating our model for ESES’s two recent transformative actions: (1) a two-step recapitalization, introducing Fir Tree Partners (FTP) as a major investor; and (2) an entry into the U.S. frac market, starting with the Mississippi Lime. FTP has purchased ESES’s $24.4M of convertible notes and 2M shares held by Albright Capital Management; accepted another $17.0M in converts; and agreed to convert the full $41.4M in notes to equity at $1.40/share, pending a shareholder vote. With its revised strategy, ESES has bolstered 2017–2018 earnings power, promisingly diversified cyclically and secularly, and positioned its Argentine operation to keep pace with, rather than await, demand. Assuming conversion, our EPS/EBITDA are cut for 2017 from ($0.05)/$9.3M to ($0.29)/$0.507M, introduced for 2018 at $0.10/ $10.0M, and our price target falls from $6.00 to $1.85.””

Esperion Therapeutics (NASDAQ:ESPR) had its hold rating reaffirmed by analysts at Royal Bank of Canada. The firm currently has a $45.00 target price on the stock.

Intra-Cellular Therapies (NASDAQ:ITCI) had its outperform rating reissued by analysts at Leerink Swann.

Jazz Pharmaceuticals plc – (NASDAQ:JAZZ) had its outperform rating reissued by analysts at Leerink Swann.

Keryx Biopharmaceuticals (NASDAQ:KERX) had its buy rating reaffirmed by analysts at Maxim Group. They currently have a $7.00 price target on the stock. The analysts wrote, “Keryx announced that the nation’s largest Medicare Part D plan sponsor has added Auryxia to its Medicare Part D plan formularies, effective immediately. Auryxia is currently indicated in the U.S. for the control of serum phosphorus levels in people with chronic kidney disease (CKD) on dialysis. Addition to these Part D plan formularies significantly increases unrestricted access to Auryxia for people on dialysis and their caregivers.””

Lennar (NYSE:LEN) had its buy rating reiterated by analysts at Royal Bank of Canada. They currently have a $53.00 target price on the stock.

Eli Lilly and (NYSE:LLY) had its outperform rating reissued by analysts at Leerink Swann.

Mallinckrodt PLC (NYSE:MNK) had its outperform rating reiterated by analysts at Leerink Swann.

Merck & Co. (NYSE:MRK) had its market perform rating reaffirmed by analysts at Leerink Swann.

Novan (NASDAQ:NOVN) had its neutral rating reaffirmed by analysts at Wedbush. The firm currently has a $8.00 target price on the stock.

NVIDIA (NASDAQ:NVDA) had its overweight rating reissued by analysts at Global Equities Research. The firm currently has a $125.00 target price on the stock.

PBF Energy (NYSE:PBF) had its hold rating reaffirmed by analysts at Royal Bank of Canada. The firm currently has a $24.00 price target on the stock.

Regal Entertainment Group (NYSE:RGC) had its buy rating reiterated by analysts at Wunderlich. Wunderlich currently has a $31.00 target price on the stock.

Ritter Pharmaceuticals (NASDAQ:RTTR) had its buy rating reiterated by analysts at Maxim Group. The analysts wrote, “Ritter shares have been weak as bloggers have been commenting on the outcome probabilities of the current P2b/3 study. We recently noted that the company has met with the FDA to discuss the statistical analysis plan (SAP) for the upcoming readout of the (N=377) study of RP-G28 in lactose intolerance One possible outcome of the meeting would be to determine if the study could be used as a single registration study” (one) plus one additional pivotal trial.””

Stemline Therapeutics (NASDAQ:STML) had its buy rating reiterated by analysts at HC Wainwright. HC Wainwright currently has a $34.00 target price on the stock.

Syros Pharmaceuticals (NASDAQ:SYRS) had its outperform rating reiterated by analysts at Wedbush. They currently have a $18.00 price target on the stock, down from their previous price target of $22.00.

TPI Composites (NASDAQ:TPIC) had its buy rating reiterated by analysts at Canaccord Genuity. The analysts wrote, “We continue to believe that ExOne gives investors a very compelling way to play the additive manufacturing space, and we think that shares are at quite attractive levels following the 4Q16 earnings report on March 16. The company has a significant opportunity within the industrial production space, and we think that global adoption of ExOne’s technologies is poised to expand. Moreover, we estimate that the company has a dominant market share within the sand binder jetting market, so the competitive threats do not appear that significant. As volumes rise —and we think they will—the company should have opportunity for expanded margins and eventually positive EBITDA. That could be a key catalyst for shares, as full-year adjusted EBITDA have been negative since the company became public.””

Terreno Realty (NYSE:TRNO) had its buy rating reiterated by analysts at National Securities. National Securities currently has a $29.00 target price on the stock, up from their previous target price of $28.00. The analysts wrote, “TRNO 4Q and FY2016 Update: First and foremost, it is important to note that approximately 89.9% of TRNO’s leased space includes pre-determined fixed rental increases or (C)onsumer (P)rice (I)ndex-based rental increases. TRNO reported 4Q16 funds from operations (“FFO”) of $10.02mln or $0.22 per share, a record high, +10.6% Q/Q and +35.5% Y/Y on $29.84mln of revenue, +15.6% Q/Q and +23.3% Y/Y. The increase in revenue and both FFO measures are attributable to TRNO’s continued robust portfolio growth, adding 917, 110 rentable square feet for the TTM period, +8.3%, with a portfolio that as of 12/31/16 stood at 11,997,484. Congruent with increases in owned square footage, revenues, and FFO, is TRNO’s dividend, which was recently raised to $0.20 per share per quarter, +11.1% Q/Q and +25% Y/Y. As management continues to look for accretive expansion opportunities and increase operating efficiencies, another 700k square feet is under contract, we expect the consistent history of dividend increases following acquisitions to continue. With industrial real estate prices up significantly and TRNO’s highly attractive acquisition vintage profile, we expect management to continue to harvest gains in 2016 and recycle capital. To date in 2016, TRNO has booked some $7.14mln in gains on $22.5mln of sales with an acquisitions cost of $16.1mln, a healthy +40.19% on a 7.05% investment CAGR. As TRNO has demonstrated in the past, it is well adept at timing the market, both on the acquisition and financing front. The future remains bright for TRNO and we continue to favor the industrial REIT operators formed in 2010 and later, as their portfolios are absent legacy assets and more attractive on a relative basis. As of September 2016, industrial RE price indices have increased 8.1% Y/Y, trailing only multifamily which is up 13.47% for the same period. We’re maintaining our BUY rating and increasing our $28.00 price target to $29.00. “

ExOne (NASDAQ:XONE) had its hold rating reissued by analysts at Canaccord Genuity. Canaccord Genuity currently has a $11.00 target price on the stock.

This story was originally published by sleekmoney (http://sleekmoney.com) and is the sole property of sleekmoney. If you are reading this article on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. You can view the original version of this story at http://sleekmoney.com/equities-research-analysts-updated-eps-estimates-for-march-20th-aapl-aig-alny-alrm-alsmy-alxn-arco-aspu-aten-axti/1709281.html

Receive News & Ratings for Apple Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Apple Inc and related companies with MarketBeat.com's FREE daily email newsletter.

 

Leave a Reply

Your email address will not be published. Required fields are marked *